DarioHealth Corp. (DRIO)
USD 0.67
(-7.25%)
USD 0.67
(-7.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 96.38 Million USD | -19.13% |
| 2022 | 119.19 Million USD | 18.28% |
| 2021 | 100.77 Million USD | 184.61% |
| 2020 | 35.4 Million USD | 44.11% |
| 2019 | 24.56 Million USD | 74.38% |
| 2018 | 14.08 Million USD | 102.52% |
| 2017 | 6.95 Million USD | 79.67% |
| 2016 | 3.87 Million USD | -23.73% |
| 2015 | 5.07 Million USD | 64.78% |
| 2014 | 3.08 Million USD | -25.14% |
| 2013 | 4.11 Million USD | 77.75% |
| 2012 | 2.31 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 122.13 Million USD | -10.83% |
| 2024 Q1 | 136.96 Million USD | 42.1% |
| 2023 Q4 | 96.38 Million USD | -9.5% |
| 2023 FY | 96.38 Million USD | -19.13% |
| 2023 Q1 | 108 Million USD | -9.38% |
| 2023 Q3 | 106.5 Million USD | -9.09% |
| 2023 Q2 | 117.15 Million USD | 8.47% |
| 2022 Q2 | 137.33 Million USD | 7.86% |
| 2022 Q3 | 126.33 Million USD | -8.01% |
| 2022 Q4 | 119.19 Million USD | -5.65% |
| 2022 FY | 119.19 Million USD | 18.28% |
| 2022 Q1 | 127.33 Million USD | 26.36% |
| 2021 Q3 | 117.18 Million USD | -10.53% |
| 2021 Q1 | 124.18 Million USD | 250.74% |
| 2021 Q4 | 100.77 Million USD | -14.01% |
| 2021 Q2 | 130.98 Million USD | 5.47% |
| 2021 FY | 100.77 Million USD | 184.61% |
| 2020 FY | 35.4 Million USD | 44.11% |
| 2020 Q1 | 20.03 Million USD | -18.46% |
| 2020 Q2 | 17.2 Million USD | -14.11% |
| 2020 Q3 | 41.14 Million USD | 139.11% |
| 2020 Q4 | 35.4 Million USD | -13.94% |
| 2019 Q2 | 12.32 Million USD | 7.81% |
| 2019 FY | 24.56 Million USD | 74.38% |
| 2019 Q3 | 8.6 Million USD | -30.2% |
| 2019 Q4 | 24.56 Million USD | 185.59% |
| 2019 Q1 | 11.43 Million USD | -18.85% |
| 2018 Q2 | 8.09 Million USD | -17.19% |
| 2018 Q1 | 9.78 Million USD | 40.58% |
| 2018 FY | 14.08 Million USD | 102.52% |
| 2018 Q4 | 14.08 Million USD | -1.7% |
| 2018 Q3 | 14.33 Million USD | 76.97% |
| 2017 Q4 | 6.95 Million USD | -26.44% |
| 2017 FY | 6.95 Million USD | 79.67% |
| 2017 Q1 | 5.98 Million USD | 54.57% |
| 2017 Q2 | 6.73 Million USD | 12.53% |
| 2017 Q3 | 9.45 Million USD | 40.42% |
| 2016 Q3 | 6.69 Million USD | -26.68% |
| 2016 Q4 | 3.87 Million USD | -42.17% |
| 2016 FY | 3.87 Million USD | -23.73% |
| 2016 Q2 | 9.13 Million USD | -16.7% |
| 2016 Q1 | 10.96 Million USD | 115.93% |
| 2015 FY | 5.07 Million USD | 64.78% |
| 2015 Q4 | 5.07 Million USD | 43.01% |
| 2015 Q3 | 3.55 Million USD | 41.72% |
| 2015 Q2 | 2.5 Million USD | -26.84% |
| 2015 Q1 | 3.42 Million USD | 11.13% |
| 2014 Q1 | 5.72 Million USD | 39.15% |
| 2014 FY | 3.08 Million USD | -25.14% |
| 2014 Q4 | 3.08 Million USD | -48.67% |
| 2014 Q3 | 6 Million USD | 76.43% |
| 2014 Q2 | 3.4 Million USD | -40.6% |
| 2013 Q2 | 9.4 Million USD | 355.57% |
| 2013 Q1 | 2.06 Million USD | -10.87% |
| 2013 FY | 4.11 Million USD | 77.75% |
| 2013 Q3 | 6.65 Million USD | -29.2% |
| 2013 Q4 | 4.11 Million USD | -38.17% |
| 2012 FY | 2.31 Million USD | 0.0% |
| 2012 Q4 | 2.31 Million USD | 12.2% |
| 2012 Q3 | 2.06 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aspira Women's Health Inc. | 6.26 Million USD | -1439.269% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -1072.394% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -599.542% |
| Standard BioTools Inc. | 323.06 Million USD | 70.164% |
| Inotiv, Inc. | 856.53 Million USD | 88.747% |
| Prenetics Global Limited | 254.17 Million USD | 62.077% |
| Neuronetics, Inc. | 115.83 Million USD | 16.785% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -10.825% |
| Castle Biosciences, Inc. | 477.81 Million USD | 79.827% |
| Psychemedics Corporation | 13.27 Million USD | -626.368% |
| RadNet, Inc. | 2.88 Billion USD | 96.661% |
| Exact Sciences Corporation | 6.47 Billion USD | 98.511% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 97.043% |
| iSpecimen Inc. | 15.81 Million USD | -509.319% |
| OpGen, Inc. | 1.88 Million USD | -5020.88% |
| Exagen Inc. | 56.94 Million USD | -69.27% |
| Bionano Genomics, Inc. | 214.4 Million USD | 55.043% |
| CareDx, Inc | 484.61 Million USD | 80.11% |
| Check-Cap Ltd. | 25.01 Million USD | -285.294% |
| Twist Bioscience Corporation | 776.4 Million USD | 87.585% |
| Guardant Health, Inc. | 1.78 Billion USD | 94.604% |
| Biodesix, Inc. | 99.09 Million USD | 2.732% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -745.533% |
| Precipio, Inc. | 18.1 Million USD | -432.506% |
| Natera, Inc. | 1.45 Billion USD | 93.385% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 92.429% |
| Sera Prognostics, Inc. | 95.44 Million USD | -0.993% |
| 23andMe Holding Co. | 395.16 Million USD | 75.608% |
| OPKO Health, Inc. | 2.01 Billion USD | 95.209% |
| Personalis, Inc. | 225.09 Million USD | 57.179% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 51.172% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -606.065% |
| T2 Biosystems, Inc. | 34.79 Million USD | -177.004% |
| Neogen Corporation | 4.58 Billion USD | 97.897% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 91.959% |
| ICON Public Limited Company | 16.98 Billion USD | 99.433% |
| NeoGenomics, Inc. | 1.68 Billion USD | 94.267% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -10.825% |
| MDxHealth SA | 129.13 Million USD | 25.356% |
| Prenetics Global Limited | 254.17 Million USD | 62.077% |
| Illumina, Inc. | 10.11 Billion USD | 99.047% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -1327.109% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 94.182% |
| Mainz Biomed B.V. | 15.4 Million USD | -525.536% |
| Trinity Biotech plc | 59.43 Million USD | -62.175% |
| Sotera Health Company | 3.13 Billion USD | 96.921% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -1072.394% |